Prevalence and risk factors of long COVID 6–12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong

• Published in: Journal of medical virology Vol. 95; no. 6; pp. e28862 - n/a
• Main Authors: Luo, Jingyuan, Zhang, Jialing, Tang, Hiu To, Wong, Hoi Ki, Lyu, Aiping, Cheung, Chun Hoi, Bian, Zhaoxiang
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.06.2023
• Subjects: Antigens; BNT162 Vaccine; Comorbidity; COVID-19 - epidemiology; COVID-19 vaccines; Diarrhea; Fatigue; Female; Hong Kong - epidemiology; Humans; Infections; Long COVID; Middle Aged; Omicron; Polymerase chain reaction; Post-Acute COVID-19 Syndrome; Prevalence; Retrospective Studies; Risk analysis; Risk Factors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; symptom; Tightness; Vaccines; Viral diseases; Virology; Hong Kong; Hong Kong China; China; risk factors; symptom; long COVID; Omicron
• ISSN: 0146-6615; 1096-9071; 1096-9071
• DOI: 10.1002/jmv.28862

Long COVID has been reported among patients with COVID‐19, but little is known about the prevalence and risk factors associated with long COVID 6–12 months after infection with the Omicron variant. This is a large‐scale retrospective study. A total of 6242 out of 12 950 nonhospitalized subjects of all ages with SARS‐CoV‐2 infection (confirmed by polymerase chain reaction/rapid antigen test) during the Omicron dominant outbreak (December 31, 2021–May 6, 2022) in Hong Kong were included. Prevalence of long COVID, frequencies of symptoms, and risk factors were analyzed. Three thousand four hundred and thirty (55.0%) subjects reported at least one long COVID symptom. The most reported symptom was fatigue (1241, 36.2%). Female gender, middle age, obesity, comorbidities, vaccination after infection, having more symptoms, and presenting fatigue/chest tightness/headache/diarrhea in the acute stage of illness were identified as associated risk factors for long COVID. Patients who had received three or more doses of vaccine were not associated with a lower risk of long COVID (adjusted odds ratio 1.105, 95% confidence interval 0.985–1.239, p = 0.088). Among patients with at least three doses of vaccine, there was no significant difference in the risk of long COVID between the CoronaVac vaccine and BNT162b2 vaccine (p > 0.05). Omicron infection can lead to long COVID in a significant proportion of nonhospitalized patients 6–12 months after infection. Further investigation is needed to uncover the mechanisms underlying the development of long COVID and determine the impact of various risk factors such as vaccines.